INTERVENTIONALACTIVE NOT RECRUITINGNCT06513507
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2024-11-21
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- NA
- Enrollment
- 12 (ACTUAL)
- Start date
- 2024-06-03
- Sponsor
- Raphael Pharma
- Design
- NA · SINGLE GROUP · TREATMENT
- Locations
- 1
- Results record
- Not present in registry snapshot
Rheumatoid ArthritisInflammatory DiseaseArthritis TreatmentCannabinoid TherapyAnti-CCP
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
Medicines
No exact medicine-name link was found.
Interventions
What was registered
DIETARY SUPPLEMENTCannabigerol (CBG)
The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 25 Years
- Maximum age
- Not reported
- Healthy volunteers
- Not accepted
Inclusion criteria
- Male or female, over 25 years of age
- Positive anti-CCP blood test
- Active RA-related inflammation with at least 2 swollen joints
- University graduate
- Generally healthy with no uncontrolled chronic disease
- Able to read, understand, and sign informed consent
- Resides in the USA
- Willing to comply with study requirements and avoid other cannabis products during the study period
Exclusion criteria
- Pre-existing chronic conditions preventing adherence
- Severe allergic reactions requiring an Epi-pen
- Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
- Pregnant or breastfeeding women
- Recent invasive medical procedure or surgery
- Active malignancy or ongoing oncology treatment
- Use of cytochrome P450 or 3A4 inhibitors
- History of substance abuse
primary outcomes
primary measures
Change in inflammatory markers from Baseline to Week 8
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
Measurement of blood levels of ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein), IL6 (Interleukin 6), and TNFa (Tumor Necrosis Factor-alpha) at Baseline, Week 2, Week 4, Week 6, and Week 8.
secondary outcomes
secondary measures
Change in self-reported symptoms and quality of life from Baseline to Week 8
Time frame: Baseline, Week 4, and Week 8
Evaluation of participant perceptions of the product's effect on symptoms of rheumatoid arthritis and quality of life using a study-specific questionnaire.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 267cebc2-0b1a-41b2-ab3c-b4e79990a1e6
- Retrieved
- 11/09/2026, 14:17:13
- SHA-256
- 77f89f35db8daefe6550ce8a386b75dc8f3a0606cc53184a0618e0d11f23efa5